Pfizer’s Streak of Returning Cash to Shareholders

Pfizer’s most recent quarterly dividend was its 331st in a row.¹ The streak stretches back more than 80 years, spanning major innovation milestones and advances in healthcare.

In the past decade, Pfizer has paired strong financial results with bold scientific breakthroughs, including the Pfizer-BioNTech COVID-19 vaccine, marketed as Comirnaty, and blockbuster medicines and vaccines such as Ibrance and Prevnar.

The company has steadily increased the quarterly dividend, most recently with a 6 percent rise from 2019 to 2020, and currently yields more than 3%. In 2020 alone, Pfizer returned approximately $8.4 billion in cash dividends to shareholders.²

[1] Pfizer Declares Third-Quarter 2021 Dividend. Available here.
[2] Proxy Statement for 2021 Annual Meeting of Shareholders. Available here.